Skip to main content
  1. Kaplan GG, Underwood FE, Coward S, Agrawal M, Ungaro RC, Brenner EJ, Gearry RB, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Zhang X, Kappelman MD, Colombel JF. The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. Inflamm Bowel Dis. 2022 Jan 15:izab339. Epub ahead of print. PMID: 35032167.
  2. Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open. 2021 Nov 12;11(11):e049740. PMID: 34772750.
  3. Izadi Z*, Brenner EJ*, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D’Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639. PMID: 34661663.
  4. Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, Kaplan GG, Kappelman MD, Ungaro RC, Colombel JF, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis. 2021 Sep 27:jjab172. PMID: 34570886.
  5. Ungaro RC*, Brenner EJ*, Agrawal M, Zhang X, Kappelman MD, Colombel JF; Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of Over 6,000 Patients from an International Registry. Gastroenterology. 2021 Sep 13. Epub ahead of print. PMID: 34529987.
  6. Ungaro RC, Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Reinisch W. New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry. Inflamm Bowel Dis. 2021 Jul 28:izab184. Epub ahead of print. PMID: 34320194.
  7. Parekh R, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD. Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2021 Jun 28:1–7. Epub ahead of print. PMID: 34181165.
  8. Agrawal M*, Brenner EJ*, Yan Mak JW, Zhang X, Kaplan GG, Ng SC, Reinisch W, Steinwurz F, Lewis JD, Kissous-Hunt M, Modesto I, Ungaro RC, Colombel JF, Kappelman MD. COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clin Gastroenterol Hepatol. 2021 Jun 2. Epub ahead of print. PMID: 34089848.
  9. Agrawal M, Zhang X, Brenner EJ, Ungaro RC, Kappelman MD, Colombel JF. The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry. J Crohns Colitis. 2021 Apr 22. Epub ahead of print. PMID: 33884425.
  10. Brenner EJ*, Ungaro RC*, Colombel JF, Kappelman MD. Reply to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients with Inflammatory Bowel Diseases: Results from an International Registry. Gastroenterology. 2021 Apr;160(5):1886-1887. Epub 2021 Jan 13. PMID: 33453233.
  11. Agrawal M, Brenner EJ, Zhang X, Modesto I, Woolcott J, Ungaro RC, Colombel JF, Kappelman MD. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. Inflamm Bowel Dis. 2021 Mar 15;27(4):585-589. PMID: 33325523
  12. Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Ungaro RC; SECURE-IBD Advisory Committee including, Gearry RB, Kalpan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry. J Crohns Colitis. 2021 May 4;15(5):860-863. PMID: 33232456.
  13. Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF**, Kappelman MD**. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021 Apr;70(4):725-732. PMID: 33082265.
  14. Brenner EJ*, Pigneur B*, Focht G, Zhang X, Ungaro RC, Colombel JF, Turner D, Kappelman MD, Ruemmele FM. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Clin Gastroenterol Hepatol. 2021 Feb;19(2):394-396.e5. PMID: 33059040.
  15. Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. IBD in the COVID-19 era: the value of international collaboration. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):887-888. PMID: 32941833.
  16. Brenner EJ*, Ungaro RC*, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020 Aug. PMID: 32425234.
  17. Brenner EJ, Kappelman MD. Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 Jan;19(1):210-211. PMID: 32246997.

* Denotes co-first authorship
** Denotes co-last authorship